2022
Hospital market concentration and the use of mechanical circulatory support devices in acute myocardial infarction complicated by cardiogenic shock
Vohra A, Jang S, Feldman D, Goyal P, Krishnan U, Sciria C, Cheung J, Kim L. Hospital market concentration and the use of mechanical circulatory support devices in acute myocardial infarction complicated by cardiogenic shock. BMC Health Services Research 2022, 22: 89. PMID: 35045849, PMCID: PMC8772168, DOI: 10.1186/s12913-021-07458-1.Peer-Reviewed Original ResearchMeSH KeywordsHeart-Assist DevicesHospital MortalityHospitalsHumansIntra-Aortic Balloon PumpingMyocardial InfarctionShock, CardiogenicUnited StatesConceptsUse of MCSMechanical circulatory supportAMI-CSAcute myocardial infarctionCardiogenic shockCirculatory supportMyocardial infarctionMechanical circulatory support devicesPrimary study exposurePrimary study outcomeMultivariable logistic regressionNational Inpatient SampleCirculatory support devicesHospital mortalityBaseline characteristicsInpatient SampleMore frequent useSubgroup analysisCompetitive hospital marketsMultivariable regressionQuery patientsStudy exposurePatientsLogistic regressionStudy outcomes
2013
Differential long‐term outcomes of zotarolimus‐eluting stents compared with sirolimus‐eluting and paclitaxel‐eluting stents in diabetic and nondiabetic patients: Two‐year subgroup analysis of the ZEST randomized trial
Jang S, Park D, Kim W, Kim Y, Yun S, Kang S, Lee S, Lee C, Park S, Park S. Differential long‐term outcomes of zotarolimus‐eluting stents compared with sirolimus‐eluting and paclitaxel‐eluting stents in diabetic and nondiabetic patients: Two‐year subgroup analysis of the ZEST randomized trial. Catheterization And Cardiovascular Interventions 2013, 81: 1106-1114. PMID: 22899589, DOI: 10.1002/ccd.24603.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary ThrombosisDiabetes MellitusDrug-Eluting StentsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPercutaneous Coronary InterventionProportional Hazards ModelsProspective StudiesProsthesis DesignRepublic of KoreaRisk AssessmentRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsZotarolimus-eluting stentsSirolimus-eluting stentsNondiabetic patientsDiabetic statusDiabetic patientsStent typeIschemia-driven target vessel revascularizationDifferential long-term outcomesLower ratesAdverse cardiac eventsComposite of deathTarget vessel revascularizationLong-term outcomesDifferential treatment effectsSimilar ratesAngiographic characteristicsIschemic complicationsCardiac eventsDiabetes mellitusPrimary outcomeMACE occurrenceStent groupMyocardial infarction